These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 36968232)
21. The impact of missing data in a generalized integer-valued autoregression model for count data. Alosh M J Biopharm Stat; 2009 Nov; 19(6):1039-54. PubMed ID: 20183463 [TBL] [Abstract][Full Text] [Related]
22. Issues with the expected information matrix of linear mixed models provided by popular statistical packages under missingness at random dropout. Thomadakis C; Pantazis N; Touloumi G Stat Med; 2023 Jul; 42(16):2873-2885. PubMed ID: 37094843 [TBL] [Abstract][Full Text] [Related]
23. A Bayesian Latent Variable Selection Model for Nonignorable Missingness. Du H; Enders C; Keller BT; Bradbury TN; Karney BR Multivariate Behav Res; 2022; 57(2-3):478-512. PubMed ID: 33529056 [TBL] [Abstract][Full Text] [Related]
24. Comparison of classical tumour growth models for patient derived and cell-line derived xenografts using the nonlinear mixed-effects framework. Voulgarelis D; Bulusu KC; Yates JWT J Biol Dyn; 2022 Dec; 16(1):160-185. PubMed ID: 35404766 [TBL] [Abstract][Full Text] [Related]
25. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Yu J; Qin B; Moyer AM; Sinnwell JP; Thompson KJ; Copland JA; Marlow LA; Miller JL; Yin P; Gao B; Minter-Dykhouse K; Tang X; McLaughlin SA; Moreno-Aspitia A; Schweitzer A; Lu Y; Hubbard J; Northfelt DW; Gray RJ; Hunt K; Conners AL; Suman VJ; Kalari KR; Ingle JN; Lou Z; Visscher DW; Weinshilboum R; Boughey JC; Goetz MP; Wang L Breast Cancer Res; 2017 Dec; 19(1):130. PubMed ID: 29212525 [TBL] [Abstract][Full Text] [Related]
26. Handling missing quality of life data in HIV clinical trials: what is practical? Fairclough DL; Thijs H; Huang IC; Finnern HW; Wu AW Qual Life Res; 2008 Feb; 17(1):61-73. PubMed ID: 18071926 [TBL] [Abstract][Full Text] [Related]
28. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers. Kanaya N; Somlo G; Wu J; Frankel P; Kai M; Liu X; Wu SV; Nguyen D; Chan N; Hsieh MY; Kirschenbaum M; Kruper L; Vito C; Badie B; Yim JH; Yuan Y; Hurria A; Peiguo C; Mortimer J; Chen S J Steroid Biochem Mol Biol; 2017 Jun; 170():65-74. PubMed ID: 27154416 [TBL] [Abstract][Full Text] [Related]
29. Misspecifying the covariance structure in a linear mixed model under MAR drop-out. Thomadakis C; Meligkotsidou L; Pantazis N; Touloumi G Stat Med; 2020 Oct; 39(23):3027-3041. PubMed ID: 32452081 [TBL] [Abstract][Full Text] [Related]
30. Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. Marshall A; Altman DG; Royston P; Holder RL BMC Med Res Methodol; 2010 Jan; 10():7. PubMed ID: 20085642 [TBL] [Abstract][Full Text] [Related]
31. Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy. Nazzal M; Sur S; Steele R; Khatun M; Patra T; Phillips N; Long J; Ray R; Ray RB Hepatology; 2020 Aug; 72(2):379-388. PubMed ID: 32356575 [TBL] [Abstract][Full Text] [Related]
32. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. Paez-Ribes M; Man S; Xu P; Kerbel RS PLoS One; 2016; 11(6):e0158034. PubMed ID: 27355476 [TBL] [Abstract][Full Text] [Related]
33. Power difference in a χ Miller ML; Roe DJ; Hu C; Bell ML BMC Med Res Methodol; 2020 Mar; 20(1):50. PubMed ID: 32122312 [TBL] [Abstract][Full Text] [Related]
34. Development and Applications of Patient-Derived Xenograft Models in Humanized Mice for Oncology and Immune-Oncology Drug Discovery. Verma B; Ritchie M; Mancini M Curr Protoc Pharmacol; 2017 Sep; 78():14.41.1-14.41.12. PubMed ID: 28892144 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of a weighting approach for performing sensitivity analysis after multiple imputation. Rezvan PH; White IR; Lee KJ; Carlin JB; Simpson JA BMC Med Res Methodol; 2015 Oct; 15():83. PubMed ID: 26464305 [TBL] [Abstract][Full Text] [Related]
36. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650 [TBL] [Abstract][Full Text] [Related]
37. Revisiting methods for modeling longitudinal and survival data: Framingham Heart Study. Ngwa JS; Cabral HJ; Cheng DM; Gagnon DR; LaValley MP; Cupples LA BMC Med Res Methodol; 2021 Feb; 21(1):29. PubMed ID: 33568059 [TBL] [Abstract][Full Text] [Related]
38. Sensitivity analysis after multiple imputation under missing at random: a weighting approach. Carpenter JR; Kenward MG; White IR Stat Methods Med Res; 2007 Jun; 16(3):259-75. PubMed ID: 17621471 [TBL] [Abstract][Full Text] [Related]
39. Bayesian sensitivity analyses for longitudinal data with dropouts that are potentially missing not at random: A high dimensional pattern-mixture model. Kaciroti NA; Little RJA Stat Med; 2021 Sep; 40(21):4609-4628. PubMed ID: 34405912 [TBL] [Abstract][Full Text] [Related]
40. Missing not at random in end of life care studies: multiple imputation and sensitivity analysis on data from the ACTION study. Carreras G; Miccinesi G; Wilcock A; Preston N; Nieboer D; Deliens L; Groenvold M; Lunder U; van der Heide A; Baccini M; BMC Med Res Methodol; 2021 Jan; 21(1):13. PubMed ID: 33422019 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]